← Back to Search

Monoclonal Antibodies

Fasenra, 30 Mg/mL Subcutaneous Solution for Asthma

Phase 4
Waitlist Available
Led By Yolanda Mageto, MD
Research Sponsored by Baylor Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 26 weeks
Awards & highlights

Study Summary

This trial will study the effects of Benralizumab in severe asthma patients with a history of allergic reactions to Aspergillus fungi.

Eligible Conditions
  • Asthma
  • Allergic Bronchopulmonary Aspergillosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~26 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 26 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of steroid requiring exacerbations
Secondary outcome measures
Asthma Control as assessed by Asthma Control Questionnaire 6
Lung Function (FEV1)
Patient-Reported Quality of Life as assessed by Saint George Respiratory Questionnaire

Side effects data

From 2016 Phase 3 trial • 220 Patients • NCT02075255
16%
Nasopharyngitis
11%
Bronchitis
8%
Headache
8%
Rhinitis
7%
Upper respiratory tract infection
5%
Sinusitis
4%
Hypertension
4%
Vertigo
3%
Back pain
3%
Pneumonia
1%
Asthma
1%
Cough
1%
Dyspnoea
1%
Cardiac failure acute
1%
Atrial fibrillation
1%
Presyncope
1%
Influenza
1%
Oesophagitis
1%
Gallbladder polyp
100%
80%
60%
40%
20%
0%
Study treatment Arm
Benra 30 mg q.8 Weeks
Benra 30 mg q.4 Weeks
Placebo

Trial Design

1Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment1 Intervention
Benralizumab treatment will be given by injections administered every 4 weeks for the first 3 injections with an additional injection eight weeks to follow for a total of 16 weeks active treatment

Find a Location

Who is running the clinical trial?

Baylor Research InstituteLead Sponsor
201 Previous Clinical Trials
203,280 Total Patients Enrolled
Yolanda Mageto, MDPrincipal InvestigatorBaylor Scott and White Health
~0 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top